TY - JOUR T1 -德国特应性哮喘和季节性变应性鼻炎的患病成本:1年回顾性研究JF -欧洲呼吸杂志JO - Eur Respir J SP - 116 LP - 122 DO - 10.1183/09031936.03.00019502 VL - 21 IS - 1 AU - Schramm, B. AU - Ehlken, B. AU - Smala, A. AU - Quednau, K. AU - Berger, K. AU - Nowak，D. Y1 - 2003/01/01 UR - //www.qdcxjkg.com/content/21/1/116.abstract N2 -本研究的目的是从第三方支付人(TPP)和患者的角度评估德国中重度特应性哮喘和/或季节性变应性鼻炎(SAR)的疾病成本。500例(276名儿童/青少年)中度至重度哮喘和/或SAR患者纳入这项横断面研究。通过特定的患者问卷和患者记录的提取来收集信息。总体而言，每位患者的年费用随着特应性哮喘的严重程度以及是否与SAR相关而增加。儿童/青少年的年平均SAR费用为1089，成人为1543。重度哮喘加SAR的年费用增加到每名儿童/青少年7,928美元，成人9,287美元。对于tpp，主要的成本驱动因素是药物、住院和康复。对患者来说，最大的成本是家庭改造。对于儿童/青少年，60-78%的支出是直接成本，而对于成年人，58%的支出是间接成本。 It was also observed that patients with moderate and severe asthma used inhaled corticosteroids less frequently than recommended by treatment guidelines. In summary, the total cost for patients increases with the severity of atopic asthma and/or seasonal allergic rhinitis and indirect costs represent a large proportion of the total cost. This study was sponsored by an unrestricted grant from Novartis Pharma GmbH, Nuremberg, Germany. ER -